AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Nuplazid - Drug Insight, 2019 - ResearchAndMarkets.com

February 19, 2019

DUBLIN--(BUSINESS WIRE)--Feb 19, 2019--The “Nuplazid - Drug Insight, 2019” report has been added to ResearchAndMarkets.com’s offering.

Nuplazid - Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location. The report covers the Global Market Assessment of the Nuplazid covering the historical global sales and also provides the Nuplazid sales estimation during the forecasted period (2019-2021).

The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country. In addition to this, the report also provides the SWOT analysis for Nuplazid and emerging therapies in this space.

Scope

Reasons to Buy

Topics Covered

1. Report Introduction

2. Nuplazid - Overview

3. Product Details

4. Nuplazid Sales Assessment

5. Patent Details

6. Global API Manufacturers Assessment

7. Market Competition

8. Emerging Therapies

9. SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/research/pglhqz/nuplazid_drug?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190219005937/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Schizophrenia Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/19/2019 02:52 PM/DISC: 02/19/2019 02:52 PM

http://www.businesswire.com/news/home/20190219005937/en